These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 21150883)

  • 1. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
    Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
    Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic carcinoma surveillance in patients with familial melanoma.
    Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
    Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
    Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
    Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
    Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
    BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial cutaneous melanoma.
    Hansson J
    Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
    De Unamuno B; García-Casado Z; Bañuls J; Requena C; Lopez-Guerrero JA; Nagore E
    Melanoma Res; 2018 Jun; 28(3):246-249. PubMed ID: 29543703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.
    Taylor NJ; Mitra N; Qian L; Avril MF; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Gruis NA; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard AL; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Yang XR; Newton-Bishop JA; Kanetsky PA;
    J Am Acad Dermatol; 2019 Aug; 81(2):386-394. PubMed ID: 30731170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
    Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
    J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
    Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
    Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.
    Berg P; Wennberg AM; Tuominen R; Sander B; Rozell BL; Platz A; Hansson J
    Melanoma Res; 2004 Aug; 14(4):251-5. PubMed ID: 15305154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline CDKN2A mutations in childhood melanoma: a case of melanoma-pancreatic cancer syndrome.
    Gironi LC; Colombo E; Farinelli P; Giorgione R; Bozzola C; Ogliara P; Pasini B
    Int J Dermatol; 2015 Dec; 54(12):e553-5. PubMed ID: 26381259
    [No Abstract]   [Full Text] [Related]  

  • 18. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
    Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
    Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
    Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
    Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.